EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Fecal Microbiota Transplantation in the Treatment Strategy of Inflammatory Bowel Disease: Molecular Mechanisms, Clinical Evidence, and the Transition Toward Defined Microbial Therapeutics

Anna Pető iD, David Sipos, Ágnes Kappéter, Zsofia Feiszt, Fanni Dembrovszky, Bernadett Halda-Kiss, Zoltán Péterfi iD

International Journal of Molecular Sciences · 08.11.2026 · 27 (21) · 10001

DOI: 10.3390/ijms272110001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.11.2026. Verfasst von Anna Pető und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Medical School, University of Pécs, 7623 Pécs, Hungary. Hauptthemen laut MEDLINE: Fecal Microbiota Transplantation, Inflammatory Bowel Diseases, Gastrointestinal Microbiome. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory Bowel Disease (IBD) comprises two clinically and pathologically distinct chronic intestinal inflammatory diseases, ulcerative colitis (UC) and Crohn’s disease (CD). Both diseases result from a dysregulated mucosal immune response to the commensal gut microbiota in genetically predisposed individuals. Because gut dysbiosis is a constant feature of both diseases, Fecal Microbiota Transplantation (FMT) has recently been investigated as a potential therapeutic strategy to restore a balanced microbiota composition in patients with IBD. There are five placebo-controlled randomized controlled trials (RCTs) in UC and several meta-analyses, which showed that treatment with FMT using material from multiple donors can lead to clinical and endoscopic remission in patients with mild-to-moderate UC and may thus double to triple the rate of remission compared with placebo (number needed to treat [NNT] ≈ 3–5). In contrast, evidence for CD is limited and inconsistent, with one promising pilot study being contrasted with a large multicenter induction trial that was stopped for futility. This review provides an update of the current molecular understanding of FMT-induced recovery of mucosal barrier function and inflammation control in intestinal inflammation (α-diversity restoration and subsequent donor strain engraftment, production of short-chain fatty acids and secondary bile acids, tryptophan–AhR signaling, IL-10-mediated induction of Tregs vs. suppression of Th17 cells and restoration of epithelial barrier function). The review also summarizes the current clinical evidence for the use of FMT in IBD, its safety, and the current regulatory status. It also describes recent developments in FMT, including the use of defined bacterial consortia, ‘live biotherapeutic products’ (LBPs), and donor–recipient pairing. Collectively, FMT provides evidence of principle for manipulating intestinal microbial ecosystems to treat immune-mediated intestinal inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fecal Microbiota TransplantationInflammatory Bowel DiseasesGastrointestinal MicrobiomeHumansAnimalsDysbiosis

Stichwörter der Autor:innen

Crohn’s diseasedysbiosisfecal microbiota transplantationgut microbiomeinflammatory bowel diseaselive biotherapeutic productsshort-chain fatty acidsulcerative colitis

Autor:innen und Institutionen

  • Department of Medical Microbiology, Medical School, University of Pécs, 7623 Pécs, Hungary.
  • 1st Department of Internal Medicine, Medical School, University of Pécs, 7623 Pécs, Hungary.
  • Department of Infectology, Somogy County Kaposi Mór Teaching Hospital, 7400 Kaposvár, Hungary.

ORCID-Profile: Anna Pető, Zoltán Péterfi

Zitieren

APA

Pető, A., Sipos, D., Kappéter, Á., Feiszt, Z., Dembrovszky, F., Halda-Kiss, B., & Péterfi, Z. (2026). Fecal Microbiota Transplantation in the Treatment Strategy of Inflammatory Bowel Disease: Molecular Mechanisms, Clinical Evidence, and the Transition Toward Defined Microbial Therapeutics. International Journal of Molecular Sciences, 27(21), 10001. https://doi.org/10.3390/ijms272110001

Vancouver

Pető A, Sipos D, Kappéter Á, Feiszt Z, Dembrovszky F, Halda-Kiss B, et al. Fecal Microbiota Transplantation in the Treatment Strategy of Inflammatory Bowel Disease: Molecular Mechanisms, Clinical Evidence, and the Transition Toward Defined Microbial Therapeutics. International Journal of Molecular Sciences. 2026;27(21):10001. doi:10.3390/ijms272110001

BibTeX
@article{Pet2026,
  author = {Pető, Anna and Sipos, David and Kappéter, Ágnes and Feiszt, Zsofia and Dembrovszky, Fanni and Halda-Kiss, Bernadett and Péterfi, Zoltán},
  title = {Fecal Microbiota Transplantation in the Treatment Strategy of Inflammatory Bowel Disease: Molecular Mechanisms, Clinical Evidence, and the Transition Toward Defined Microbial Therapeutics},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {10001},
  doi = {10.3390/ijms272110001}
}
Kostenlos starten →